FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912208436> ?p ?o ?g. }

• W2912208436 endingPage "S92" @default.
• W2912208436 startingPage "S91" @default.
• W2912208436 abstract "BackgroundMucopolysaccharidosis type IH (MPS1/Hurler Syndrome), cerebral adrenoleukodystrophy (cALD), metachromatic leukodystrophy (MLD) and globoid cell leukodystrophy (GLD) are fatal IMDs affecting the central nervous system treatable through allogeneic hematopoietic stem cell transplantation (HSCT). In the absence of a non-carrier HLA matched related donor, cord blood (CB) is the preferred source of cells in IMDs due to rapid availability and flexibility in matching. However, prolonged neutropenia and high graft failure rates present a challenge, particularly with reduced intensity conditioning regimens. MGTA-456 is produced from a single CB unit using an aryl hydrocarbon receptor antagonist in a 15-day expansion culture of CD34+ cells. In previous phase 1/2 studies, hematologic malignancy patients treated with myeloablative conditioning and MGTA-456, with median 324-fold CD34+ expansion, showed 100% engraftment with a 9 day reduction in time to neutrophil recovery. As higher CD34+ doses have been correlated with improved engraftment in IMD transplant patients, we hypothesize MGTA-456 may reduce duration of neutropenia and risk of graft failure and more rapidly correct the metabolic deficiency in IMD patients.Patients and MethodsA Phase 2, open-label trial (NCT03406962) initiated in Feb 2018 is enrolling up to 12 patients <16 yo with a diagnosis of MPS1, cALD, MLD, or GLD. Eligible CB units are matched at ≥ 6 of 8 HLA loci. The reduced toxicity conditioning regimen consists of anti-thymocyte globulin (days -9 to -6), fludarabine (40 mg/m2 x4 days) and busulfan (total exposure 21,000 to 22,000 μM/min/L−1 x4 days). Immunoprophylaxis consists of cyclosporin and methylprednisolone.ResultsFive patients have been treated per protocol to date (Figure 1). MGTA-456 contained a median 561-fold expansion of CD34+ cells after culture with a median infused CD34+ cell dose of 110 × 106 cells/kg and median total nucleated cell dose of 26.4 × 107 (Figure 2). The median duration of neutropenia was 1 day (range 0-9), in contrast to a median of 8 days for a historical cohort (Figure 3). Myeloid chimerism was ≥98% donor by day +14 in evaluable patients. Two patients developed autoimmune cytopenia, a known complication in IMD patients after HSCT, unrelated to MGTA-456. Time to discharge after transplant was a median of 19.5 days at time of reporting. Preliminary data from MPS1 patients demonstrated normalization of blood alpha-L-iduronidase enzyme activity and decreased urinary glycosoaminoglycan levels after transplant.ConclusionsTreatment of IMD patients with MGTA-456 showed early and robust engraftment in all patients with marked reduction in days of neutropenia compared to a historical cohort. These preliminary data, in combination with the previous hematologic malignancy patients treated, suggest MGTA-456 substantially enhances engraftment and rate of neutrophil recovery. Mucopolysaccharidosis type IH (MPS1/Hurler Syndrome), cerebral adrenoleukodystrophy (cALD), metachromatic leukodystrophy (MLD) and globoid cell leukodystrophy (GLD) are fatal IMDs affecting the central nervous system treatable through allogeneic hematopoietic stem cell transplantation (HSCT). In the absence of a non-carrier HLA matched related donor, cord blood (CB) is the preferred source of cells in IMDs due to rapid availability and flexibility in matching. However, prolonged neutropenia and high graft failure rates present a challenge, particularly with reduced intensity conditioning regimens. MGTA-456 is produced from a single CB unit using an aryl hydrocarbon receptor antagonist in a 15-day expansion culture of CD34+ cells. In previous phase 1/2 studies, hematologic malignancy patients treated with myeloablative conditioning and MGTA-456, with median 324-fold CD34+ expansion, showed 100% engraftment with a 9 day reduction in time to neutrophil recovery. As higher CD34+ doses have been correlated with improved engraftment in IMD transplant patients, we hypothesize MGTA-456 may reduce duration of neutropenia and risk of graft failure and more rapidly correct the metabolic deficiency in IMD patients. A Phase 2, open-label trial (NCT03406962) initiated in Feb 2018 is enrolling up to 12 patients <16 yo with a diagnosis of MPS1, cALD, MLD, or GLD. Eligible CB units are matched at ≥ 6 of 8 HLA loci. The reduced toxicity conditioning regimen consists of anti-thymocyte globulin (days -9 to -6), fludarabine (40 mg/m2 x4 days) and busulfan (total exposure 21,000 to 22,000 μM/min/L−1 x4 days). Immunoprophylaxis consists of cyclosporin and methylprednisolone. Five patients have been treated per protocol to date (Figure 1). MGTA-456 contained a median 561-fold expansion of CD34+ cells after culture with a median infused CD34+ cell dose of 110 × 106 cells/kg and median total nucleated cell dose of 26.4 × 107 (Figure 2). The median duration of neutropenia was 1 day (range 0-9), in contrast to a median of 8 days for a historical cohort (Figure 3). Myeloid chimerism was ≥98% donor by day +14 in evaluable patients. Two patients developed autoimmune cytopenia, a known complication in IMD patients after HSCT, unrelated to MGTA-456. Time to discharge after transplant was a median of 19.5 days at time of reporting. Preliminary data from MPS1 patients demonstrated normalization of blood alpha-L-iduronidase enzyme activity and decreased urinary glycosoaminoglycan levels after transplant. Treatment of IMD patients with MGTA-456 showed early and robust engraftment in all patients with marked reduction in days of neutropenia compared to a historical cohort. These preliminary data, in combination with the previous hematologic malignancy patients treated, suggest MGTA-456 substantially enhances engraftment and rate of neutrophil recovery." @default.
• W2912208436 created "2019-02-21" @default.
• W2912208436 creator A5017478741 @default.
• W2912208436 creator A5029596053 @default.
• W2912208436 creator A5033661466 @default.
• W2912208436 creator A5035571112 @default.
• W2912208436 creator A5040518837 @default.
• W2912208436 creator A5051468151 @default.
• W2912208436 creator A5052367348 @default.
• W2912208436 creator A5067564170 @default.
• W2912208436 creator A5079500075 @default.
• W2912208436 creator A5082698708 @default.
• W2912208436 creator A5087156523 @default.
• W2912208436 creator A5090936468 @default.
• W2912208436 date "2019-03-01" @default.
• W2912208436 modified "2023-09-27" @default.
• W2912208436 title "Robust Engraftment with Mgta-456, a CD34+ Expanded Cell Therapy Product in Patients with Inherited Metabolic Disorders (IMD): Preliminary Phase 2 Trial Results" @default.
• W2912208436 doi "https://doi.org/10.1016/j.bbmt.2018.12.171" @default.
• W2912208436 hasPublicationYear "2019" @default.
• W2912208436 type Work @default.
• W2912208436 sameAs 2912208436 @default.
• W2912208436 citedByCount "0" @default.
• W2912208436 crossrefType "journal-article" @default.
• W2912208436 hasAuthorship W2912208436A5017478741 @default.
• W2912208436 hasAuthorship W2912208436A5029596053 @default.
• W2912208436 hasAuthorship W2912208436A5033661466 @default.
• W2912208436 hasAuthorship W2912208436A5035571112 @default.
• W2912208436 hasAuthorship W2912208436A5040518837 @default.
• W2912208436 hasAuthorship W2912208436A5051468151 @default.
• W2912208436 hasAuthorship W2912208436A5052367348 @default.
• W2912208436 hasAuthorship W2912208436A5067564170 @default.
• W2912208436 hasAuthorship W2912208436A5079500075 @default.
• W2912208436 hasAuthorship W2912208436A5082698708 @default.
• W2912208436 hasAuthorship W2912208436A5087156523 @default.
• W2912208436 hasAuthorship W2912208436A5090936468 @default.
• W2912208436 hasBestOaLocation W29122084361 @default.
• W2912208436 hasConcept C126322002 @default.
• W2912208436 hasConcept C142724271 @default.
• W2912208436 hasConcept C203014093 @default.
• W2912208436 hasConcept C2776326100 @default.
• W2912208436 hasConcept C2776694085 @default.
• W2912208436 hasConcept C2776755627 @default.
• W2912208436 hasConcept C2777063308 @default.
• W2912208436 hasConcept C2777408962 @default.
• W2912208436 hasConcept C2777636572 @default.
• W2912208436 hasConcept C2778684742 @default.
• W2912208436 hasConcept C2779134260 @default.
• W2912208436 hasConcept C2779263901 @default.
• W2912208436 hasConcept C2911091166 @default.
• W2912208436 hasConcept C71924100 @default.
• W2912208436 hasConcept C90924648 @default.
• W2912208436 hasConceptScore W2912208436C126322002 @default.
• W2912208436 hasConceptScore W2912208436C142724271 @default.
• W2912208436 hasConceptScore W2912208436C203014093 @default.
• W2912208436 hasConceptScore W2912208436C2776326100 @default.
• W2912208436 hasConceptScore W2912208436C2776694085 @default.
• W2912208436 hasConceptScore W2912208436C2776755627 @default.
• W2912208436 hasConceptScore W2912208436C2777063308 @default.
• W2912208436 hasConceptScore W2912208436C2777408962 @default.
• W2912208436 hasConceptScore W2912208436C2777636572 @default.
• W2912208436 hasConceptScore W2912208436C2778684742 @default.
• W2912208436 hasConceptScore W2912208436C2779134260 @default.
• W2912208436 hasConceptScore W2912208436C2779263901 @default.
• W2912208436 hasConceptScore W2912208436C2911091166 @default.
• W2912208436 hasConceptScore W2912208436C71924100 @default.
• W2912208436 hasConceptScore W2912208436C90924648 @default.
• W2912208436 hasIssue "3" @default.
• W2912208436 hasLocation W29122084361 @default.
• W2912208436 hasOpenAccess W2912208436 @default.
• W2912208436 hasPrimaryLocation W29122084361 @default.
• W2912208436 hasRelatedWork W2107334994 @default.
• W2912208436 hasRelatedWork W2287181492 @default.
• W2912208436 hasRelatedWork W2374949105 @default.
• W2912208436 hasRelatedWork W2391054219 @default.
• W2912208436 hasRelatedWork W2551399872 @default.
• W2912208436 hasRelatedWork W2562728710 @default.
• W2912208436 hasRelatedWork W2609272607 @default.
• W2912208436 hasRelatedWork W2914729568 @default.
• W2912208436 hasRelatedWork W3094049319 @default.
• W2912208436 hasRelatedWork W4310956126 @default.
• W2912208436 hasVolume "25" @default.
• W2912208436 isParatext "false" @default.
• W2912208436 isRetracted "false" @default.
• W2912208436 magId "2912208436" @default.
• W2912208436 workType "article" @default.